TTR and atrial fibrillation: Clinical trials have investigated ASOs for lowering low-density lipoprotein cholesterol (LDL-C) [39], lowering transthyretin (TTR) blood levels [40,41,42], reducing atrial fibrillation burden [43], reducing serum lipoprotein (a) levels [44], and preventing neovascular glaucoma [45].